The ICORG 10-05 clinical trial was initiated to investigate the efficacy of docetaxel (T)/carboplatin (C) with trastuzumab (H) or lapatinib (L) or the combination (HL) based on pCR to neo-adjuvant therapy in HER2+ breast cancer patients. Here, ERBB2 is linked to breast carcinoma.